India Pharma Outlook Team | Tuesday, 10 March 2026
AbbVie has reported encouraging early data for its experimental ABBV-295 obesity drug, announcing positive topline results from the multiple ascending dose portion of a Phase 1 clinical trial evaluating ABBV-295.
The study explored the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with an average body mass index below 30 kg/m².
The ABBV-295 obesity drug is designed as a long-acting amylin analog, offering a different biological approach from widely used GLP-1 and GIP receptor therapies. Amylin-based treatments work by helping regulate appetite and metabolism, which researchers believe could support sustained weight loss in people living with Obesity.
Also Read: Advancing Interventional Radiology in India Through Collaboration
The Phase 1 study included mostly male participants, who represented 88.3 percent of the trial population. Researchers tested doses ranging from 2 mg to 14 mg using different titration schedules and dosing frequencies. Across the study groups, the therapy was generally well tolerated. Most reported side effects were mild gastrointestinal symptoms, mainly occurring during the first six weeks of treatment.
Results showed clear, dose-dependent weight loss over the 12–13 week trial period. Participants receiving weekly doses recorded least-squares mean body weight reductions between 7.75 percent and 9.79 percent at week 12. Those receiving the therapy every other week or monthly experienced reductions ranging from 7.86 percent to 9.73 percent at week 13. Placebo groups saw little to no change in body weight.
“Obesity is a complex, chronic disease that places a substantial burden on patients, healthcare systems and society, and there remains a critical need for therapies that combine efficacy with tolerability and support long-term adherence,” said Primal Kaur, senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie.
